SCHEMBL3869900

SCHEMBL3869900

Cc1ccc(-c2ccc(C(=O)NCCc3ccc(C(C)N4CCN(C)CC4)cc3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
MCHR1 Q99705 6/20 0.47
CHRM1 P11229 2/20 0.47
HTR2A P28223 2/20 0.47
CYP2D6 P10635 1/20 0.47
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.46
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CCR3 P51677 1/20 0.45
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872340 0.91 ALDH1A1 (0.58) NPC1RAB9AALDH1A1SMN1; SMN2MCHR1
SCHEMBL3875329 0.91 MCHR1 (0.60) NPC1RAB9AALDH1A1SMN1; SMN2MCHR1
SCHEMBL3876383 0.91 MCHR1 (0.59) NPC1RAB9ASMN1; SMN2MCHR1CHRM1
SCHEMBL3870079 0.90 ALDH1A1 (0.57) NPC1RAB9AALDH1A1SMN1; SMN2MCHR1
SCHEMBL3870885 0.90 ALDH1A1 (0.57) NPC1RAB9AALDH1A1SMN1; SMN2MCHR1
SCHEMBL3879855 0.89 KDM4E (0.54) NPC1RAB9AALDH1A1SMN1; SMN2LMNA
SCHEMBL3868991 0.87 MCHR1 (0.49) NPC1RAB9AALDH1A1SMN1; SMN2MCHR1
SCHEMBL3868881 0.85 TRPV1 (0.51) ALDH1A1SMN1; SMN2CHRM1
SCHEMBL3868712 0.83 MCHR1 (0.55) NPC1RAB9AALDH1A1SMN1; SMN2MCHR1
SCHEMBL3869079 0.82 CHRM4 (0.50) NPC1RAB9AALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R NPC1 2114/4885RAB9A 1092/4885ALDH1A1 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.